Frontlight ResearchEarly access
Taking peopleNo phase
MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK
Key facts
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Where
- Switzerland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 56 people, planned
- Started
- 1 Jun 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Observational, 2 groups
- Record updated
- 2 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Septic shock:
- New onset (<24h) of septic shock diagnosis according to Sepsis-3 definition
- (suspected) infection
- Vasopressors required to maintain mean arterial pressure ≥65mm Hg (despite adequate fluid resuscitation)
- Serum lactate level > 2mmol/L
- Minimum age of 18 years
- Expected length of stay >48h
- Written consent from an independent physician; Critically ill:
- Patients on mechanical ventilation (MV) in the ICU without an admission diagnosis of sepsis/septic shock according to Sepsis-3 definition
- Minimum age of 18 years
- Expected length of stay >48h
- Written consent from an independent physician
Who cannot take part
- Patients with known; Pre-existing congenital or acquired severe immune deficiency (e.g. severe combined immunodeficiency, HIV infection, AIDS) or; current immunosuppressive therapy (immunosuppressive biologicals or active lymphocyte therapy e.g. endoxan, rituximab or corticosteroid use at a dose > 10 mg/day equivalent of prednisone. However, acute corticosteroid treatment of a relative adrenal insufficiency using a maximum hydrocortisone dose of 200 mg/day is accepted
- Age < 18 years
- Patients known not to speak German or French
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis-induced immunosuppression (SIS) is a common complication in patients with septic shock. Reduced expression of Human leukocyte antigen isotype DR (HLA-DR) on circulating monocytes is a marker for SIS and correlates with risk of secondary infections and mortality. The miRSep study aims to improve the understanding of early microRNA (miRNA) mediated changes in HLA-DR on monocytes in patients with septic shock.
The 2 groups in the trial
- Septic shock
Patients in ICU with diagnosed septic shock
- Critically ill patients
Critically ill patients in ICU without sepsis diagnosis
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- MIRSEP - MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK
- Record updated
- 2 June 2026